Back to top
more

Centogene (CNTG)

(Delayed Data from NSDQ)

$0.46 USD

0.46
79,404

-0.01 (-1.11%)

Updated Apr 19, 2024 03:41 PM ET

After-Market: $0.47 +0.01 (3.09%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Patterson Cos. (PDCO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 20% and 3.85%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -200% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Sema4 Holdings Corp. (SMFR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sema4 Holdings Corp. (SMFR) delivered earnings and revenue surprises of -5.26% and 8.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sangoma Technologies Corporation (SANG) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangoma Technologies Corporation (SANG) delivered earnings and revenue surprises of 62.50% and 2.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 1.41% and 9.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Computer Programs and Systems (CPSI) Q3 Earnings Lag Estimates

by Zacks Equity Research

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -13.64% and 0.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -400% and 7.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -25% and 12.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Q3 Earnings Beat Estimates

by Zacks Equity Research

Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Change Healthcare (CHNG) Q4 Earnings Miss Estimates

by Zacks Equity Research

Change Healthcare (CHNG) delivered earnings and revenue surprises of -9.30% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Centogene N.V. (CNTG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Centogene N.V. (CNTG) delivered earnings and revenue surprises of -83.05% and 11.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for September 10th

by Zacks Equity Research

CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021

Centogene N.V. (CNTG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Centogene N.V. (CNTG) Stock Jumps 7.5%: Will It Continue to Soar?

by Zacks Equity Research

Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner

by Zacks Equity Research

Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner

Urmimala Biswas headshot

3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases

by Urmimala Biswas

The Zacks Medical Info Systems industry is gaining from growing demand for digital healthcare support. However, drop in COVID-19 cases might disrupt this uptrend. Industry players CPSI, CNTG and CERN are set to gain the most.